Acquisitions21 Feb 2025, 03:43 am
Senores Pharmaceuticals Acquires Roflumilast ANDA from Breckenridge Pharmaceutical, Inc.
AI Summary
Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., has signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for ‘Roflumilast’ 250 mcg and 500 mcg tablets from Breckenridge Pharmaceutical, Inc. The acquisition will be funded through the Initial Public Offer (IPO) proceeds. The market size of Roflumilast in the USA is around USD 32 Mn (MAT June 2024) and USD 46 Mn (MAT September 2024). This strategic acquisition expands Senores' portfolio into specialty distribution and helps establish a presence in the chronic bronchitis therapy area.
Key Highlights
- Senores Pharmaceuticals acquires Roflumilast 250 mcg and 500 mcg tablets ANDA from Breckenridge Pharmaceutical, Inc.
- The acquisition will be funded through the Initial Public Offer (IPO) proceeds.
- Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis and a history of exacerbations.
- The market size of Roflumilast in the USA is around USD 32 Mn (MAT June 2024) and USD 46 Mn (MAT September 2024).
- This strategic acquisition expands Senores' portfolio into specialty distribution and helps establish a presence in the chronic bronchitis therapy area.